Bristol-Myers Squibb Co., founded in 1887 and headquartered in New York City, is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. The company focuses on a range of therapeutic areas, including oncology, immunology, cardiovascular diseases, and fibrosis, with blockbuster products like Opdivo and Eliquis leading its portfolio.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Bristol-Myers Squibb first began issuing bonds in the 1990s, with a notable $1 billion issuance in 2020 to help fund its acquisition of Celgene, a transformative move aimed at enhancing its oncology pipeline. Currently, its bond offerings typically yield in line with industry averages, reflecting strong credit ratings and market confidence. Recently, the company has issued green bonds, showcasing its commitment to sustainability, and its bonds are distinguished by features such as call options, providing flexibility in refinancing as market conditions evolve.